XKRX
041830
Market cap506mUSD
Oct 08, Last price
51,000.00KRW
1D
-3.95%
1Q
-2.86%
Jan 2017
88.89%
IPO
402.46%
Name
InBody Co Ltd
Chart & performance
P/E
22.21
P/S
2.91
EPS
2,296.05
Div yield, %
0.78%
Shrs. gr., 5y
0.12%
Rev. gr., 5y
16.91%
Revenues
233.95b
+14.42%
Net income
30.63b
-7.57%
CFO
35.78b
+25.20%
Dividend
Mar 30, 2026600 KRW/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
InBody Co.,Ltd is a global provider of advanced body composition analysis solutions. The company offers an extensive product line, including body composition analyzers, blood pressure monitors, stadiometers, and body water analyzers, along with specialized devices like the InBody Dial and various bands. These technologies are widely employed across diverse applications, such as medical specialties like nephrology, liver disease, and diabetes, as well as in nutrition and rehabilitation programs. Originally established in 1996 and headquartered in Seoul, South Korea, the company was formerly known as Biospace Co., Ltd.
Key people
Gyeong Ho Yoo
Vice President, Director · since 2011
Taek Seon Kim
Internal Auditor · since 2011
Gi Cheol Cha
Chairman, Chief Executive Officer · since 2024
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||